Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18
Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Related Posts
Creating Images Via AI? Google Launches Tools To Detect Fake Images And Curb Misinformation
Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG) plans to add new features to its Image Search tool to help users find the authentic source of an image in a bid to identify misleading AI pictures.
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Housing Market Correction: Rates Up, Lack Of Buyers, Cracks Forming In Home Improvement
The housing market, still in its relentless rough patch as mortgage rates continue to climb higher, is deterring buyers from making a move.